LabCanvas

Graphical abstract template · Cancer biology · Graphical abstract

Immune checkpoint blockade

A figure of checkpoint blockade in cancer immunotherapy. The 3D immune-synapse model shows PD-1/PD-L1 engaged — recruiting SHP-2 to switch the T cell off — then an anti-PD-1 antibody and an anti-CTLA-4 antibody releasing the brake. It sets out where each checkpoint acts (CTLA-4 at priming in the lymph node, PD-1/PD-L1 at the effector phase in the tumour) and names the approved antibodies.

Updated 3 cited papers54 editable layers

Immune checkpoint blockade: preview of the editable figure template
Preview at reduced size. The full figure opens in the editor, where every layer can be changed.

At a glance

Category
Cancer biology
Method
Graphical abstract
Product
How checkpoint antibodies release the brakes on anti-tumour T cells
Key result
The TCR–pMHC close contact spans ~13–15 nm, excluding the large phosphatase CD45 (kinetic segregation) (Davis & van der Merwe 2006)
Figure
1920 × 1080 px (16:9), 54 editable layers

Step by step

  1. Brake engagedPD-L1 on the tumour cell binds PD-1 on the T cell, which recruits the phosphatase SHP-2 to its ITIM/ITSM and damps TCR signalling (Pardoll 2012)
  2. Anti-PD-1 / anti-PD-L1An antibody wedged between PD-1 and PD-L1 frees the T cell; nivolumab and pembrolizumab block PD-1, atezolizumab blocks PD-L1 (Ribas & Wolchok 2018)
  3. Anti-CTLA-4CTLA-4 outcompetes CD28 for CD80/86 at priming; ipilimumab blocks CTLA-4 in the lymph node (Pardoll 2012)
  4. Two sites of actionCTLA-4 acts at T-cell priming in the lymph node; PD-1/PD-L1 acts at the effector phase in the tumour; LAG-3 is a third target (relatlimab) (Ribas & Wolchok 2018)

Uses

  • Immuno-oncology review and graphical-abstract figures
  • Talks on checkpoint inhibitors
  • Teaching the two sites of checkpoint action

Papers this template follows

  1. Pardoll, “The blockade of immune checkpoints in cancer immunotherapy”, Nat. Rev. Cancer 2012. doi:10.1038/nrc3239review
  2. Ribas & Wolchok, “Cancer immunotherapy using checkpoint blockade”, Science 2018. doi:10.1126/science.aar4060review
  3. Davis & van der Merwe, “The kinetic-segregation model: TCR triggering and beyond”, Nat. Immunol. 2006. doi:10.1038/ni1369primary

Drawn in LabCanvas after Pardoll, Nat. Rev. Cancer 2012 (doi:10.1038/nrc3239); Ribas & Wolchok, Science 2018 (doi:10.1126/science.aar4060); and Davis & van der Merwe, Nat. Immunol. 2006 (doi:10.1038/ni1369). Ectodomains enlarged to read; schematic.

How templates are written and checked: editorial guidelines.

Questions

What does the “Immune checkpoint blockade” template show?

A figure of checkpoint blockade in cancer immunotherapy. The 3D immune-synapse model shows PD-1/PD-L1 engaged — recruiting SHP-2 to switch the T cell off — then an anti-PD-1 antibody and an anti-CTLA-4 antibody releasing the brake. It sets out where each checkpoint acts (CTLA-4 at priming in the lymph node, PD-1/PD-L1 at the effector phase in the tumour) and names the approved antibodies.

What are the steps shown in “Immune checkpoint blockade”?

1. Brake engaged: PD-L1 on the tumour cell binds PD-1 on the T cell, which recruits the phosphatase SHP-2 to its ITIM/ITSM and damps TCR signalling (Pardoll 2012). 2. Anti-PD-1 / anti-PD-L1: An antibody wedged between PD-1 and PD-L1 frees the T cell; nivolumab and pembrolizumab block PD-1, atezolizumab blocks PD-L1 (Ribas & Wolchok 2018). 3. Anti-CTLA-4: CTLA-4 outcompetes CD28 for CD80/86 at priming; ipilimumab blocks CTLA-4 in the lymph node (Pardoll 2012). 4. Two sites of action: CTLA-4 acts at T-cell priming in the lymph node; PD-1/PD-L1 acts at the effector phase in the tumour; LAG-3 is a third target (relatlimab) (Ribas & Wolchok 2018).

Which papers is “Immune checkpoint blockade” based on?

Pardoll, “The blockade of immune checkpoints in cancer immunotherapy”, Nat. Rev. Cancer 2012 (doi:10.1038/nrc3239); Ribas & Wolchok, “Cancer immunotherapy using checkpoint blockade”, Science 2018 (doi:10.1126/science.aar4060); Davis & van der Merwe, “The kinetic-segregation model: TCR triggering and beyond”, Nat. Immunol. 2006 (doi:10.1038/ni1369).

Can I edit the “Immune checkpoint blockade” template?

Yes. Open it in the LabCanvas editor: all 54 layers are editable. Change the text, colours and layout, then export PNG, TIFF or PDF at the width and DPI the journal asks for.

Do I need an account to use this template?

Not to view it here. To open and edit it, sign in to LabCanvas or create a free account (the free plan keeps up to 3 designs). Downloading the figure is part of LabCanvas Pro (US$19 a month or US$199 a year).

immune checkpointcheckpoint blockadePD-1PD-L1CTLA-4LAG-3nivolumabpembrolizumabatezolizumabipilimumabrelatlimabimmunotherapyimmune synapseSHP-2graphical abstract3D model

More in Cancer biology

All 256 templates

Start from this template

Open “Immune checkpoint blockade” in the editor and make it your own.

Open in the editor Sign in
Immune checkpoint blockadeOpen in the editor